已出刊文章

【綜合評述】新型NaV1.8 阻斷劑suzetrigine 於急性疼痛治療之應用
Application of Suzetrigine, a Novel NaV1.8 Inhibitor, in the Treatment of Acute Pain
suzetrigine、急性疼痛、鈉離子通道阻斷劑、疼痛控制、suzetrigine, acute pain, sodium channel blockers, pain control
蔡奕萱I-Hsuan Tsai1 、楊璦瑜Ai-Yu Yang1,*
1高雄醫學大學附設中和紀念醫院 藥學部

摘要
中重度急性疼痛的治療長期依賴類鴉片藥物,但伴隨成癮性、耐受性及相關死亡率上升等安全疑慮。傳統非類鴉片止痛藥如非類固醇類消炎止痛藥與acetaminophen,療效有限且有副作用風險。Suzetrigine 為美國食品藥物管理局2025 年1 月核准上市的口服止痛藥,是二十多年來首個核准用於中重度急性疼痛的非類鴉片藥物。
Suzetrigine 為高選擇性電壓門控鈉通道1.8 (NaV1.8) 抑制劑,對NaV1.8 的抑制效力較其他鈉通道亞型高達31,000 倍以上。NaV1.8 選擇性表達於周圍感覺神經元,在中樞神經系統不表達,因此不具類鴉片相關的中樞副作用或成癮性。建議劑量為起始單次空腹100 mg,之後每12 小時50 mg 維持劑量,療程不超過14 天。
第二期與第三期臨床試驗證實,suzetrigin 在腹部整形術與拇趾外翻切除術後能顯著減輕中重度急性疼痛,療效與類鴉片藥物相當但未達優越性。與hydrocodone/acetaminophen 相比,噁心嘔吐發生率更低。濫用風險評估顯示無成癮或濫用風險。可單獨使用或與acetaminophen、ibuprofen 併用作為多模式止痛。
然而suzetrigine 仍面臨挑戰,長期安全性數據尚不足、特殊族群使用資料有限、藥物交互作用需注意(特別是CYP3A4 抑制劑或誘導劑)、慢性疼痛適應症尚未確立。此藥品的核准為急性疼痛控制開啟新篇章,有望減少類鴉片藥物造成的公共衛生危機,為無法耐受類鴉片的患者提供新選擇。
 
ABSTRACT
Moderate-to-severe acute pain management has long relied on opioids, which are associated with addiction, tolerance, and rising mortality rates. Traditional nonopioid analgesics such as non-steroid anti-inflammatory drugs and acetaminophen have limited efficacy and adverse effect risks. Suzetrigine, approved by the U.S. Food and Drug Administration in January 2025, is the first non-opioid medication approved for moderate-to-severe acute pain in over two decades.
Suzetrigine is a highly selective voltage-gated sodium channel 1.8 (NaV1.8) inhibitor, with selectivity over 31,000-fold greater than other sodium channel subtypes. NaV1.8 is selectively expressed in peripheral sensory neurons and absent in the central nervous system, thereby avoiding opioid-related central side effects and addiction potential. The recommended dosage is an initial 100 mg dose administered on an empty stomach, followed by 50 mg every 12 hours, with the treatment duration not exceeding 14 days.
Phase 2 and 3 clinical trials demonstrated that suzetrigine significantly reduced moderate-to-severe acute pain following abdominoplasty and bunionectomy, with efficacy comparable to opioids but without demonstrating superiority. Compared with hydrocodone/acetaminophen, suzetrigine showed a lower incidence of nausea and vomiting. Abuse potential assessments revealed no evidence of addiction or abuse risk. It can be used alone or in combination with acetaminophen or ibuprofen as part of a multimodal analgesic strategy.
However, challenges remain, including limited long-term safety data, insufficient data in special populations, potential drug interactions (particularly with CYP3A4 inhibitors or inducers), and the lack of established indications for chronic pain. The approval of suzetrigine represents a breakthrough in acute pain management and may help address the opioid public health crisis.
 
Submitted for publication: 2025.10.11; Accepted for publication: 2026.01.05

操作進行中,請稍候~~~~
×
加载中...

系統通知

不再顯示此通知
×